CTLA4 and neoplasm: MC38 tumor–bearing animals treated with mANK-101 or systemic PD-1 blockade alone each had a tumor-free survival rate of 40%, whereas the combination of ANK-101 and CTLA-4 blockade had tumor-free survival rates of 70% and 80% with concurrent or sequential therapy, respectively (data not shown).